I am grateful for the benefits that [Company Name] provides and for the companys stated commitment to employee wellbeing, equity, and longterm health
Looking Back on GLP-1 RAs Originally discovered in the saliva of the Gila monster, exenatide a GLP-1 RA was approved as a twice-daily injection by the FDA in 2005 for adults with type 2 diabetes
Porous silicon microparticles enable sustained release of GLP-1R agonist peptides for the treatment of Type 2 diabetes
As a result, GLP-1s are only likely to grow in popularity
By activating GLP-1 and GIP receptors, it enhances insulin secretion (when glucose is present) and suppresses appetite, similar to existing incretin therapies [7] [8]
GLP-1 handles appetite suppression and slows gastric emptying, keeping you satisfied longer after meals